Literature DB >> 11228054

Transient thyrotoxicosis and hypothyroidism following administration of the GnRH agonist leuprolide acetate.

S Kasayama1, S Miyake, Y Samejima.   

Abstract

A 45-year-old women with chronic idiopathic thrombocytopenic purpura was given monthly injections of the GnRH agonist leuprolide acetate for the treatment of uterine leiomyoma. Two weeks after the fifth injection, she showed mild symptoms of thyrotoxicosis. At that time, serum thyroxin (T4) and triiodothyronine (T3) levels were elevated whereas TSH level was suppressed. Anti-thyroglobulin (anti-Tg) and anti-thyroid peroxidase (anti-TPO) antibodies were positive, whereas TSH binding inhibitory immunoglobulin (TBII) was undetectable. Two months later, serum T4 and T3 levels spontaneously decreased below the normal ranges. Five months after the onset of the disease, they returned to normal without any treatment. Anti-TPO and anti-Tg antibodies gradually decreased during the clinical course. Thus, the present case was indicated to be an instance wherein silent thyroiditis developed after leuprolide acetate administration. This is the first report to demonstrate the association of thyroid disorder with leuprolide injection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11228054     DOI: 10.1507/endocrj.47.783

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males.

Authors:  Jason H Mateika; Qasim Omran; J A Rowley; X S Zhou; M P Diamond; M Safwan Badr
Journal:  J Physiol       Date:  2004-09-16       Impact factor: 5.182

2.  Painless thyroiditis occurring during post-menopausal period, following remission of Graves' disease.

Authors:  S Kasayama; T Kitamura; M Inaba; M Otsuki; N Asanuma; H Kouhara
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

3.  Thyroid dysfunction associated with administration of the long-acting gonadotropin-releasing hormone agonist.

Authors:  Eun Jin Han; Ha Do Song; Ji Hoon Yang; So Young Park; Sung Hoon Kim; Hyun Koo Yoon; Chang Hoon Yim
Journal:  Endocrinol Metab (Seoul)       Date:  2013-09-13

4.  Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis.

Authors:  Naoki Gocho; Ema Aoki; Chiho Okada; Takeshi Hirashima
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

5.  Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity.

Authors:  Loris Marin; Guido Ambrosini; Marco Noventa; Flavia Filippi; Eugenio Ragazzi; Francesco Dessole; Giampiero Capobianco; Alessandra Andrisani
Journal:  Int J Endocrinol       Date:  2022-04-12       Impact factor: 2.803

6.  Thyroid heterogeneity, as indicated by the CV of ultrasonographic intensities, correlates with anti-thyroid peroxidase antibodies in euthyroid Hashimoto's thyroiditis.

Authors:  Yosuke Wakita; Toshiki Nagasaki; Yuki Nagata; Yasuo Imanishi; Shinsuke Yamada; Koichiro Yoda; Masanori Emoto; Eiji Ishimura; Masaaki Inaba
Journal:  Thyroid Res       Date:  2013-03-23

7.  FANCA Polymorphism Is Associated with the Rate of Proliferation in Uterine Leiomyoma in Korea.

Authors:  Eunyoung Ha; Seungmee Lee; So Min Lee; Jeeyeon Jung; Hyewon Chung; Eunsom Choi; Sun Young Kwon; Min Ho Cha; So-Jin Shin
Journal:  J Pers Med       Date:  2020-11-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.